MX377447B - Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis. - Google Patents

Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis.

Info

Publication number
MX377447B
MX377447B MX2015011671A MX2015011671A MX377447B MX 377447 B MX377447 B MX 377447B MX 2015011671 A MX2015011671 A MX 2015011671A MX 2015011671 A MX2015011671 A MX 2015011671A MX 377447 B MX377447 B MX 377447B
Authority
MX
Mexico
Prior art keywords
zoledronic acid
administration
steroids
osteoarthritis
prevent
Prior art date
Application number
MX2015011671A
Other languages
English (en)
Spanish (es)
Other versions
MX2015011671A (es
Inventor
Ketan Desai
Original Assignee
Levolta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Levolta Pharmaceuticals Inc filed Critical Levolta Pharmaceuticals Inc
Publication of MX2015011671A publication Critical patent/MX2015011671A/es
Publication of MX377447B publication Critical patent/MX377447B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
MX2015011671A 2013-03-08 2014-03-07 Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis. MX377447B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/791,685 US9012432B2 (en) 2013-03-08 2013-03-08 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
PCT/US2014/022169 WO2014138712A1 (en) 2013-03-08 2014-03-07 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis

Publications (2)

Publication Number Publication Date
MX2015011671A MX2015011671A (es) 2016-05-12
MX377447B true MX377447B (es) 2025-03-10

Family

ID=51488530

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011671A MX377447B (es) 2013-03-08 2014-03-07 Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis.

Country Status (12)

Country Link
US (1) US9012432B2 (cg-RX-API-DMAC10.html)
EP (1) EP2964209B1 (cg-RX-API-DMAC10.html)
JP (2) JP6839491B2 (cg-RX-API-DMAC10.html)
KR (1) KR102253394B1 (cg-RX-API-DMAC10.html)
CN (1) CN105324113B (cg-RX-API-DMAC10.html)
AU (1) AU2014225373B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015021503B1 (cg-RX-API-DMAC10.html)
CA (1) CA2941346C (cg-RX-API-DMAC10.html)
EA (1) EA032067B1 (cg-RX-API-DMAC10.html)
ES (1) ES2904365T3 (cg-RX-API-DMAC10.html)
MX (1) MX377447B (cg-RX-API-DMAC10.html)
WO (1) WO2014138712A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3428178A4 (en) 2016-03-09 2019-09-04 Bio Pep Co., Ltd. PEPTIDE FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES AND USE THEREOF
WO2017155234A1 (ko) 2016-03-09 2017-09-14 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
KR101897122B1 (ko) 2016-03-09 2018-09-10 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
US10913772B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
US10913771B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
JP7127616B2 (ja) 2019-06-04 2022-08-30 横河電機株式会社 情報処理装置、アラーム管理システム、及びアラーム管理方法
WO2021163432A1 (en) * 2020-02-12 2021-08-19 Levolta Pharmaceuticals, Inc. Co-administration of prednisolone/methyl prednisolone and zoledronic acid to treat and prevent osteoarthritis
CN114028571B (zh) * 2021-11-18 2023-04-28 中国医学科学院基础医学研究所 含氮双膦酸盐联合糖皮质激素在预防或治疗病毒性肺炎中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2038692T4 (es) 1986-11-21 2012-02-10 Novartis Ag Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.
WO2001047559A1 (fr) * 1999-12-27 2001-07-05 Teikoku Seiyaku Co., Ltd Pastilles a usage externe
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
EP1402066A4 (en) * 2001-06-08 2008-10-22 Ortho Mcneil Pharm Inc PAIN TREATMENT WITH HYPERPOLARIZATION ACTIVATED CHANNELS CONTROLLED BY CYCLIC NUCLEOTIDE AS ATTACK POINT
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
AU2004273672A1 (en) * 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate
JP2008502609A (ja) * 2004-06-17 2008-01-31 オステオロジックス エイ／エス リウマチおよび関節性疾患の治療改善方法
ES2396976T3 (es) * 2005-05-25 2013-03-01 Calosyn Pharma, Inc Método y composición para tratar osteoartritis
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
PT2049123E (pt) * 2006-08-03 2013-03-06 Horizon Pharma Ag Tratamento de doença reumatóide com glucocorticóide de libertação retardada
US20100158905A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy of arthritis with tranilast
EP2427160A4 (en) * 2009-05-04 2012-12-19 Zars Pharma Inc METHOD FOR TREATING PAIN RELATED TO NEUROMAS, NERVE CLAIMS AND OTHER SUFFERING PAINS
US8946199B2 (en) 2010-04-26 2015-02-03 Ketan Desai Co-administration of steroids and Zoledronic acid to prevent and treat side effects from Zoledronic acid infusion

Also Published As

Publication number Publication date
JP6839491B2 (ja) 2021-03-17
EP2964209A1 (en) 2016-01-13
EA032067B1 (ru) 2019-04-30
CA2941346A1 (en) 2014-09-12
BR112015021503B1 (pt) 2022-09-06
EA201591638A1 (ru) 2016-02-29
ES2904365T3 (es) 2022-04-04
EP2964209B1 (en) 2021-10-27
US9012432B2 (en) 2015-04-21
KR20150125001A (ko) 2015-11-06
MX2015011671A (es) 2016-05-12
CN105324113B (zh) 2018-07-03
EP2964209A4 (en) 2016-08-03
AU2014225373A1 (en) 2015-10-22
AU2014225373B2 (en) 2018-07-05
CA2941346C (en) 2020-03-10
CN105324113A (zh) 2016-02-10
JP2019104762A (ja) 2019-06-27
BR112015021503A2 (en) 2018-05-15
KR102253394B1 (ko) 2021-05-20
JP2016510765A (ja) 2016-04-11
US20140256681A1 (en) 2014-09-11
WO2014138712A1 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
MX2021004828A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
WO2014197632A3 (en) Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
PT2958945T (pt) Terapia de combinação envolvendo anticorpos contra claudina 18.2 para tratamento de cancro
MX364705B (es) Sistemas y metodos para tratar el cancer y/o aumentar la funcion de organos.
EA201591638A1 (ru) Совместное введение стероидов и золедроновой кислоты для профилактики и лечения остеоартрита
MX2020003174A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer.
IL242386B (en) Use of Aribolin and Lavetinib as a combination therapy for cancer treatment
EP4292550A3 (en) Anchor delivery system
MX2016005532A (es) Metodos para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
EP3141603A4 (en) Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
BR112015023020A2 (pt) combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas
NI201500151A (es) Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata.
NI201500150A (es) TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método
MX374749B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
MX2015014344A (es) Terapia contra el cancer.
TW201613599A (en) Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease
EP2969008A4 (en) MEDICATION FOR THE TREATMENT OF CANCER, CARDIOVASCULAR DISEASES AND INFLAMMATION
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
RU2014150855A (ru) Способ лечения сексуальной дисфункции у пациентов с хроническим простатитом
UA82380U (ru) Способ лечения гайморитов

Legal Events

Date Code Title Description
FG Grant or registration